AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33162329
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (pre-exercise: 0.084 g kg−1 BW; during exercise: 0.056 g kg−1 h−1)
Trial: 33162329
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution (non-caloric)
Trial: 36221338
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus extract 1000 mg per day
Trial: 36221338
Drug: Phellinus linteus
RxNorm normalized name: PHELLINUS LINTEUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phellinus linteus extract 2000 mg per day
Trial: 36221338
Drug: Placebo (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2000 mg of dextrin per day)
Trial: 34988780
Drug: Immediate-release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release formulation
Trial: 34561872
Drug: High-volume Foley
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume Foley catheter (60 ml) and vaginal misoprostol
Trial: 32749459
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of allogeneic cardiosphere-derived cells (CDCs)
Trial: 33126051
Drug: More precise
RxNorm normalized name: Sore No More
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More precise dosing with 0.5 mg acenocoumarol increments
Trial: 33126051
Drug: Conventional dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dosing with 1.0 mg acenocoumarol increments
Trial: 34417217
Drug: Internet-based cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive-behavioural therapy (ICBT)
Trial: 35982162
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 supplementation (1000 µg cyanocobalamin per day for 12 weeks)
Trial: 32157328
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch (0 mg)
Trial: 36173237
Drug: Bionic Pancreas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bionic Pancreas (BP) with insulin aspart or insulin lispro
Trial: 32248163
Drug: Antiseptic solution
RxNorm normalized name: ANTISEPTIC SOLUTION
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiseptic solution 'Decasan'; probiotic 'BioGaia ProDentis'; immune modulator 'Imupret'
Trial: 36367997
Drug: 12 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 cycles of adjuvant fluorouracil, leucovorin, and oxaliplatin chemotherapy
Trial: 36367997
Drug: Exercising ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercising ≥ 9 MET-hours per week after treatment
Trial: 33421928
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (ozonized rectal insufflation and minor auto haemotherapy) along with standard of care (SOC)
Trial: 32020853
Drug: A. konjac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A. konjac extract capsules (5 mg glycosylceramides)
Trial: 34699271
Drug: Transoral surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transoral surgery (TOS) plus 66 Gy postoperative radiation therapy (RT) and weekly cisplatin
Trial: 33843410
Drug: Semi-immersive Virtual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-immersive Virtual Reality navigation therapy (vSail-Access®), 30-40 min per day, three times per week for six weeks
Trial: 36878996
Drug: N-acetylcysteine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (1200 mg twice daily)
Trial: 33682983
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 10 mg/kg daily divided into 2 doses every 12 h
Trial: 35006266
Drug: Intravenous edaravone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous edaravone
Trial: 35006266
Drug: Riluzole only
RxNorm normalized name: Riluzole only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riluzole only (standard therapy)
Trial: 35749997
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TXA) 5 mg/kg
Trial: 33954850
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal treatment (NSPT) in the +PE+RA group
Trial: 35709376
Drug: Budesonide 4
RxNorm normalized name: budesonide 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 4 mg suppository
Trial: 35709376
Drug: Budesonide 2
RxNorm normalized name: budesonide 2 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 2 mg foam
Trial: 38172996
Drug: 250 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 μg/day B12 supplementation
Trial: 33297826
Drug: Complete Decongestive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Decongestive Therapy (CDT) plus exercises
Trial: 33297826
Drug: Intermittent Pneumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Pneumatic Compression Therapy (IPCT) plus exercises
Trial: 36409969
Drug: CBD oil
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (NATURAL) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD OIL 3000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD oil (100 mg/mL, 0.5 mL once daily to 2 mL three times a day)
Trial: 36564395
Drug: Rifampin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (600 mg)
Trial: 33166694
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg on Day 1 followed by 400 mg once weekly for 3 weeks
Trial: 35285904
Drug: 38% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% hydrogen peroxide bleaching treatment
Trial: 34581025
Drug: AS04-HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-HPV-16/18 vaccine (90% of Arm A and 90% of Arm B girls)
Trial: 34581025
Drug: AS04-HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-HPV-16/18 vaccine (90% of Arm B girls)
Trial: 34581025
Drug: AS04-HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS04-HPV-16/18 vaccine (in pooled Arms A/B)
Trial: 34581025
Drug: HBV vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV vaccine (10% of Arm A girls and all boys in Arm B, all participants in Arm C)
Trial: 35742702
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive non-surgical periodontal therapy (MINST)
Trial: 35742702
Drug: Conventional non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional non-surgical periodontal therapy (CNST)
Trial: 32068914
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg)
Trial: 35831874
Drug: Fluralaner (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluralaner (oral dose)
Trial: 32946590
Drug: XBS +
RxNorm normalized name: Xylometazoline hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XBS + 10 × 10^6 PDL-MSCs/100 mg
Trial: 35534312
Drug: Intradermal fractional-dose
RxNorm normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with dmLT
Trial: 35534312
Drug: Fractionated dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated dose of intradermal IPV without dmLT
Trial: 32865597
Drug: Dulaglutide (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (weekly for 24 weeks)
Trial: 33731569
Drug: Calcium hydroxylapatite
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxylapatite with lidocaine (3 mL total, 1 to 2 syringes)
Trial: 34156873
Drug: In-clinic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-clinic therapy
Trial: 34605319
Drug: Ofatumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (20 mg every 4 weeks, subcutaneous via autoinjector)
Trial: 34605319
Drug: Ofatumumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (20 mg every 4 weeks, subcutaneous via PFS)
Trial: 34605319
Drug: Ofatumumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (both administration methods)
Trial: 32435011
Drug: Dual lipid‐lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual lipid‐lowering therapy (DLLT) with ezetimibe and atorvastatin
Trial: 35654052
Drug: Ibrutinib plus
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib plus venetoclax (ibrutinib: 420 mg once daily; venetoclax: weekly ramp-up from 20 mg to 400 mg once daily)
Trial: 35654052
Drug: Treatment cessation
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment cessation
Trial: 35654052
Drug: Ibrutinib monotherapy
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib monotherapy (for patients not randomly assigned)
Trial: 32019598
Drug: Subcutaneous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous paracetamol
Trial: 35767384
Drug: Remestemcel-L (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remestemcel-L (150 million MSCs)
Trial: 33368307
Drug: Tezepelumab 210
RxNorm normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tezepelumab 210 mg subcutaneously every 4 weeks
Trial: 33368307
Drug: Tezepelumab doses
RxNorm normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tezepelumab doses up to 280 mg every 2 weeks
Trial: 36091030
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg qw
Trial: 36091030
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (etanercept + celecoxib)
Trial: 35766128
Drug: Nemolizumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab 0.5 mg/kg SC
Trial: 34196132
Drug: Oral busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral busulfan vs. intravenous busulfan
Trial: 32266380
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of aspirin once daily
Trial: 34962561
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for aspirin
Trial: 34962561
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ω-3 fatty acids once daily
Trial: 35265304
Drug: Capecitabine sequential
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine sequential treatment for 4 cycles
Trial: 35265304
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sequential treatment)
Trial: 32100452
Drug: Sequential boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy (fluorouracil 600 mg/m2 days 1-3 and cisplatin 25 mg/m2 days 1-3, every 4 weeks for 4 cycles)
Trial: 32100452
Drug: Sequential boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy
Trial: 35028170
Drug: Chamomile extract
RxNorm normalized name: Chamomile Extract
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chamomile extract cream
Trial: 33046528
Drug: laryngeal mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: laryngeal mask airway and i-gel
Trial: 33175143
Drug: Nomogram including
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nomogram including mixed histological types, chemotherapy, and primary site surgery as factors.
Trial: 35946018
Drug: Preanesthetic fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preanesthetic fluid loading with Ringer's lactate (20 mL/kg over 30 minutes)
Trial: 35946018
Drug: No preloading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preloading (2 mL/kg/h maintenance)
Trial: 32805028
Drug: Avocado consumption
RxNorm normalized name: Avocado
DrugBank: Avocado (DB10504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avocado consumption (175 g for men; 140 g for women) once daily for 12 weeks
Trial: 35524695
Drug: Daily fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fortified balanced energy-protein supplement and an iron-folic acid (IFA) tablet
Trial: 35524695
Drug: IFA tablet
RxNorm normalized name: immune globulin intravenous (human) - ifas Injection [Panzyga]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFA tablet only
Trial: 33523106
Drug: AA:DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA:DHA supplementation (100 mg/kg/d of AA and 50 mg/kg/d of DHA)
Trial: 33389189
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg 2 hours before surgery
Trial: 33389189
Drug: TAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block with 60 mL 0.25% levobupivacaine after general anesthesia
Trial: 33389189
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg 2 hours before surgery and 50 mg rectal diclofenac sodium on recovery from general anesthesia
Trial: 35869503
Drug: automated, theory‐informed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: automated, theory‐informed text messages daily for 12 months plus endowment incentives linked to verified weight loss targets at 3, 6 and 12 months
Trial: 34656640
Drug: Cholecalciferol 50,000
RxNorm normalized name: CHOLECALCIFEROL 50,000UNIT TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 50,000 U weekly for 8 weeks followed by 10,000 U weekly for 44 weeks
Trial: 34444963
Drug: 688 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 688 mg/day palmiteolate (omega-7 fatty acid supplementation)
Trial: 35104737
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg donepezil hydrochloride (test formulation)
Trial: 35104737
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg donepezil hydrochloride (reference formulation)
Trial: 35001501
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 25 mg tablet once daily, switched from Efavirenz (EFV) plus two NRTIs for ≥3 months
Trial: 35001501
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) 25 mg tablet once daily
Trial: 34913149
Drug: Jiuwei Zhuhuang
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Jiuwei Zhuhuang Powder (JWZH) 1 to 1.5 g, twice to thrice daily for 5 days
Trial: 34913149
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules, 0.25 to 1 g, thrice daily for 5 days)
Trial: 34913149
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Pediatric Paracetamol, Artificial Cow‐bezoar and Chlorphenamine Maleate Granules)
Trial: 33813585
Drug: High-concentration phospholipid
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration phospholipid eye spray (Tears Again)
Trial: 33813585
Drug: Low-concentration phospholipid
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration phospholipid eye spray (Ocuvers)
Trial: 32739652
Drug: Clopidogrel monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel monotherapy for 9 months
Trial: 32739652
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus clopidogrel for 9 months followed by aspirin monotherapy for 3 months
Trial: 34044526
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 0.5 mg/mL combined with triamcinolone
Trial: 34044526
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 5.0 mg/mL combined with triamcinolone
Trial: 34044526
Drug: 5-fluorouracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil at 12.5 mg/mL combined with triamcinolone
Trial: 33121503
Drug: FTC‐TDF or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTC‐TDF or FTC‐TAF (over 1 or 2 days, with final dose given either 6 or 20 hours prior to surgery)
Trial: 33259621
Drug: Multistrategic, community-wide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multistrategic, community-wide interventions using social marketing techniques and network intervention (e.g., word of mouth) over 5 years
Trial: 35556389
Drug: 2-week lithium
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week lithium treatment (40 mmol/kg/food)
Trial: 35556389
Drug: 4-week lithium
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week lithium treatment (40 mmol/kg/food)
Trial: 33007353
Drug: Patiromer (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patiromer (starting doses ranged from 8.4 to 33.6 g/day)
Trial: 33949680
Drug: Written communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written communication via leaflet with visual aids (L-VA)
Trial: 33949680
Drug: Written communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written communication via leaflet with no visual aids (L-NVA)
Trial: 35143607
Drug: REST intervention
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: REST intervention (occupational therapist‐led cognitive‐behavioral therapy for insomnia)
Trial: 34211988
Drug: 308-nm excimer
RxNorm normalized name: NM-004
DrugBank: NM-004 (DB18066)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 308-nm excimer lamp monotherapy
Trial: 34211988
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 308-nm excimer lamp and 10% liquor carbonis detergens
Trial: 33414533
Drug: Systemic mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic mycophenolate mofetil (MMF) 1 g orally twice daily for the first 6 months, then 1 g daily for the next 6 months, plus corticosteroids
Trial: 33414533
Drug: Topical 0.03%
RxNorm normalized name: tacrolimus topical 0.03% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.03% tacrolimus four times a day for 12 months, plus corticosteroids
Trial: 35543937
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with regular treatment and swallowing function training
Trial: 35543937
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular treatment and swallowing function training only)
Trial: 32698033
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic ointment
Trial: 32698033
Drug: Placebo (mineral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mineral oil and petrolatum‐based) ointment
Trial: 34002252
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous injection of teriparatide 56.5 μg for 72 weeks
Trial: 36239756
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with alendronate for 120 weeks
Trial: 35974359
Drug: Standard antipyretic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antipyretic treatment from the participating hospital.
Trial: 33221636
Drug: Standardized intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized intervention group (SIG) - brief perioperative smoking cessation intervention with nicotine patch therapy for 8 weeks
Trial: 35341647
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose (SD, 5x10^10 viral particles)